Market Newsdesk

Semtech and Ripl Networks to Deliver IoT Tracking Solution for the U.S. Department of Defense with LoRa®

Collaboration integrates Semtech’s LoRa® devices with Ripl Networks’ IP mesh, 3D location tracking software to help secure naval ports

CAMARILLO, Calif.–(BUSINESS WIRE)–Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, announced Ripl Networks, the leader in IP networking for low power devices, has been selected by the U.S. Department of Defense (DoD) to deploy an IP mesh, 3D tracking solution for foreign guest and fleet assets at naval ports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005234/en/

Semtech’s LoRa® devices provide the long range, low-bandwidth connectivity for Ripl’s IP over low power devices messaging system called MLMesh™. Ripl’s software enables Tiny Edge computing where low cost, machine learning emitters can live inside the Enterprise IP network. The combined technology enables low power devices to talk Internet Protocol (IP) at long distances while accurately tracking 3D locations without GPS or cellular towers.

“Ripl lets Tiny-Edge computers talk IP creating a long distance, wire-free extension of the IP WAN,” said Kerry Shih, CEO of Ripl Networks. “LoRa devices’ proven distance and low power enables Ripl to offer an IP fabric up to 20km from node to node with a battery life up to 10 years.”

The DoD was searching for 3D tracking of assets in a private, IP network that would support low power sensors. “After what we’ve seen demonstrated around the Port of Hueneme, I trust we’ll continue to see investment in progressive technologies like Tiny Edge computing and Ripl MLMesh,” said Alan Jaeger, Director of NavalX Ventura TechBridge at the Department of Navy. “Ripl and LoRa combine to secure this new class of networked computers using IP infrastructure versus creating a second data network just for IoT.”

The Port of Hueneme, the only deep-water harbor between Los Angeles and the San Francisco Bay area, will be the first DoD deployment of the asset tracking solution. Port of Hueneme CEO & Port Director Kristin Decas said, “We are proud of our long history of vigilance when it comes to security on the port. Ripl will help further that mission with real-time, 3D location tracking of assets for which we are responsible.”

Ripl Networks will act as the systems integrator with other key technologies, including Avnet’s IoT Connect platform, which will serve as the backend system for data storage and monitoring.

“Semtech’s LoRa platform enables the rapid and scalable deployment of military-grade applications, such as Ripl Networks’ asset tracking solution,” said Marc Pegulu, Vice President of IoT Product Marketing for Semtech’s Wireless and Sensing Products Group. “We are pleased to assist the U.S. Department of Defense in its efforts to monitor and secure critical American assets.”

About Semtech’s LoRa® Platform

Semtech’s LoRa device-to-Cloud platform is a globally adopted long range, low power solution for IoT applications, enabling the rapid development and deployment of ultra-low power, cost efficient and long range IoT networks, gateways, sensors, module products, and IoT services worldwide. Semtech’s LoRa devices provide the communication layer for the LoRaWAN® protocol, which is maintained by the LoRa Alliance®, an open IoT alliance for Low Power Wide Area Network (LPWAN) applications that has been used to deploy IoT networks in over 100 countries. Semtech is a founding member of the LoRa Alliance. To learn more about how LoRa enables IoT, visit Semtech’s LoRa site.

About Semtech

Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the Nasdaq Global Select Market under the symbol SMTC. For more information, visit www.semtech.com.

About Ripl Networks

Ripl Networks accelerates IoT adoption by economically bringing sensors into the Enterprise’s IP realm. The Ripl Networks MLMesh system reduces the cost of implementing, administering and maintaining IoT projects and leverages the Enterprise’s existing investment in IP knowledge and networks to do so. Ripl software, devices and reference designs remove threats to the industry achieving its vast potential by slashing dependencies on specialized expertise and extending the obvious and solid momentum of IPv6 for IoT.

Forward-Looking and Cautionary Statements

All statements contained herein that are not statements of historical fact, including statements that use the words “to deploy,” “can,” “enables,” “to offer,” “will,” “efforts to,” “designed to” or other similar words or expressions, that describe Semtech Corporation’s or its management’s future plans, objectives or goals are “forward-looking statements” and are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Semtech Corporation to be materially different from the historical results and/or from any future results or outcomes expressed or implied by such forward-looking statements. Such factors are further addressed in Semtech Corporation’s annual and quarterly reports, and in other documents or reports, filed with the Securities and Exchange Commission (www.sec.gov) including, without limitation, information under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Semtech Corporation assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law.

Semtech, the Semtech logo and LoRa are registered trademarks or service marks of Semtech Corporation or its affiliates.

SMTC-P

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005234/en/

Ronda Grech

Semtech Corporation

(805) 250-1263

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Engineering Manufacturing Maritime Defense Transport Telecommunications Contracts Networks Internet Hardware Semiconductor Security

MEDIA:

Logo

Photo

Semtech and Ripl (Graphic: Business Wire)

TESSCO Urges Shareholders to Sign and Return GREEN Consent Revocation Card to Maintain Board Balance

Mr. Barnhill’s Pursuit of Control of TESSCO’s Board is Not in the Best Interests of Shareholders

HUNT VALLEY, Md.–(BUSINESS WIRE)–
TESSCO Technologies Incorporated (NASDAQ: TESS), a leading value-added distributor and solutions provider for the wireless industry, today sent the following letter to shareholders urging them to sign and return TESSCO’s GREEN consent revocation card in order to prevent Robert B. Barnhill Jr. from taking control of TESSCO’s Board of Directors:

December 3, 2020

Dear TESSCO Shareholder,

We are writing to urge you to sign and return the GREEN consent revocation card to ensure that Mr. Barnhill cannot take control of the TESSCO Board by replacing a majority of the directors with his handpicked nominees.

Mr. Barnhill continues to assert that his goal is a refreshed Board. Yet, the TESSCO Board has already been substantially refreshed with five new directors added in the last three years. In fact, the Special Committee of the Board is open to more refreshment, and has attempted to work with Mr. Barnhill to reach a settlement under which two of Mr. Barnhill’s nominees would be added to the Board. Mr. Barnhill has rebuffed these attempts, and has not even responded to TESSCO’s most recent proposal or made any other effort to find a way to end this expensive and disruptive consent solicitation. It is time to allow our CEO, Sandip Mukerjee, and the rest of the management team to focus on their strategic plan and prioritize TESSCO’s turnaround to deliver value to shareholders.

Why is Mr. Barnhill refusing to engage in an effort to reach a resolution that is aligned with the preferred outcomes of independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) and in the best interest of all shareholders? Why is he still seeking control of the Board when both ISS and Glass Lewis indicated that shareholders would not be best served by Mr. Barnhill and his nominees obtaining control?

It is clear that Mr. Barnhill is not seeking what is best for TESSCO or its shareholders, but is instead focused on securing control of the TESSCO Board.

If shareholders consent to Mr. Barnhill’s plan, Mr. Barnhill will gain significant influence, and given his lackluster track record when in control, this will not enable TESSCO to achieve its long-term goals. It is imperative that shareholders protect the future of their investment and prevent Mr. Barnhill and his nominees from gaining control of the TESSCO Board by signing and returning the enclosed GREEN Consent Revocation Card TODAY.

TESSCO shareholders are reminded that their vote is important, no matter how many or how few shares they own. TESSCO urges you to support the TESSCO settlement proposal and your company’s Board by signing, dating and returning the enclosed GREEN Consent Revocation Card TODAY. If you receive a White Consent Card from Robert B. Barnhill, Jr., please disregard it.

If you have any questions or need assistance executing your revocation,

please contact TESSCO’s proxy solicitor,

Innisfree M&A Incorporated

Shareholders may call toll-free: (877) 800-5195

Banks and Brokers may call collect: (212) 750-5833

Sidley Austin LLP and Ballard Spahr LLP are serving as legal counsel to the Special Committee of TESSCO’s Board of Directors.

About TESSCO Technologies Incorporated (NASDAQ: TESS)

TESSCO Technologies, Inc. (NASDAQ: TESS) is a value-added technology distributor, manufacturer, and solutions provider serving commercial and retail customers in the wireless infrastructure and mobile device accessories markets. The company was founded more than 30 years ago with a commitment to deliver industry-leading products, knowledge, solutions, and customer service. TESSCO supplies more than 46,000 products from 350 of the industry’s top manufacturers in mobile communications, Wi-Fi, Internet of Things (“IoT”), wireless backhaul, and more. TESSCO is a single source for outstanding customer experience, expert knowledge, and complete end-to-end solutions for the wireless industry. For more information, visit www.tessco.com.

Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans and future prospects, and our expectations for future operations, are forward-looking statements. These forward-looking statements are based on current expectations and analysis, and actual results may differ materially from those projected. These forward-looking statements may generally be identified by the use of the words “may,” “will,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “seeks,” “believes,” “estimates,” and similar expressions, but the absence of these words or phrases does not necessarily mean that a statement is not forward-looking. These forward-looking statements are only predictions and involve a number of risks, uncertainties and assumptions, many of which are outside of our control. Our actual results may differ materially and adversely from those described in or contemplated by any such forward-looking statement for a variety of reasons, including those risks identified in our most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission (the “SEC”), under the heading “Risk Factors” and otherwise. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject. For additional information with respect to risks and other factors which could occur, see Tessco’s Annual Report on Form 10-K for the year ended March 29, 2020, including Part I, Item 1A, “Risk Factors” therein, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other securities filings with the SEC that are available at the SEC’s website at www.sec.gov and other securities regulators.

We are not able to identify or control all circumstances that could occur in the future that may materially and adversely affect our business and operating results. Without limiting the risks that we describe in our periodic reports and elsewhere, among the risks that could lead to a materially adverse impact on our business or operating results are the following: the impact and results of the consent solicitation and other activism activities by Robert B. Barnhill, Jr. and certain other participants in his consent solicitation and/or other activist investors, termination or non-renewal of limited duration agreements or arrangements with our vendors and affinity partners that are typically terminable by either party upon several months or otherwise relatively short notice; loss of significant customers or relationships, including affinity relationships; loss of customers either directly or indirectly as a result of consolidation among large wireless services carriers and others within the wireless communications industry; the strength of our customers’, vendors’ and affinity partners’ business; negative or adverse economic conditions, including those adversely affecting consumer confidence or consumer or business spending or otherwise adversely impacting our vendors or customers, including their access to capital or liquidity, or our customers’ demand for, or ability to fund or pay for, the purchase of our products and services; our dependence on a relatively small number of suppliers and vendors, which could hamper our ability to maintain appropriate inventory levels and meet customer demand; changes in customer and product mix that affect gross margin; effect of “conflict minerals” regulations on the supply and cost of certain of our products; failure of our information technology system or distribution system; system security or data protection breaches; technology changes in the wireless communications industry or technological failures, which could lead to significant inventory obsolescence and/or our inability to offer key products that our customers demand; third-party freight carrier interruption; increased competition from competitors, including manufacturers or national and regional distributors of the products we sell and the absence of significant barriers to entry which could result in pricing and other pressures on profitability and market share; our relative bargaining power and inability to negotiate favorable terms with our vendors and customers; our inability to access capital and obtain financing as and when needed; transitional and other risks associated with acquisitions of companies that we may undertake in an effort to expand our business; claims against us for breach of the intellectual property rights of third parties; product liability claims; our inability to protect certain intellectual property, including systems and technologies on which we rely; our inability to hire or retain for any reason our key professionals, management and staff; health epidemics or pandemics or other outbreaks or events, or national or world events or disasters beyond our control; and the possibility that, for unforeseen or other reasons, we may be delayed in entering into or performing, or may fail to enter into or perform, anticipated contracts or may otherwise be delayed in realizing or fail to realize anticipated revenues or anticipated savings.

The above list should not be construed as exhaustive and should be read in conjunction with our other disclosures, including but not limited to the risk factors described in our most recent Annual Report on Form 10-K and other periodic reports filed with the SEC, under the heading “Risk Factors” and otherwise. Other risks may be described from time to time in our filings made under the securities laws. New risks emerge from time to time. It is not possible for our management to predict all risks.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. We disclaim any duty to update any of these forward-looking statements after the date of this press release to confirm these statements to actual results or revised expectations.

Important Additional Information and Where to Find It

In connection with the consent solicitation initiated by Robert B. Barnhill, Jr. and certain other participants, TESSCO Technologies Incorporated (the “Company”) has filed a consent revocation statement and accompanying GREEN consent revocation card and other relevant documents with the Securities and Exchange Commission (the “SEC”). SHAREHOLDERS ARE STRONGLY ENCOURAGED TO CAREFULLY READ THE COMPANY’S CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), ACCOMPANYING GREEN CONSENT REVOCATION CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a free copy of the consent revocation statement, any amendments or supplements to the consent revocation statement and other documents that the Company files with the SEC at the SEC’s website at www.sec.gov or the Company’s website at https://ir.tessco.com as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005291/en/

Cindy King, TESSCO

+1 410 229 1161 or [email protected]

Media

Jeff Kauth / Aiden Woglom

Joele Frank Wilkinson Brimmer Katcher

(212) 355-4449

Investors

Larry Miller / Gabrielle Wolf

Innisfree M&A Incorporated

Phone: (212) 750-5833

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Technology Mobile/Wireless Internet Other Technology

MEDIA:

Posted on December 3, 2020 8:04 am

The Call of Duty Endowment Announces the Second Annual C.O.D.E. Bowl on December 11

The Call of Duty Endowment Announces the Second Annual C.O.D.E. Bowl on December 11

Presented by USAA, First Ever Trans-Atlantic Military Esports Competition Brings Together Top Streamers and Teams from All U.S. Department of Defense Military Branches and UK Branches To Raise Funds for Veteran Employment

Teams to Compete in the Newly-Released Call of Duty: Black Ops Cold War, Coached by Call of Duty League Pros

SANTA MONICA, Calif.–(BUSINESS WIRE)–
The Call of Duty Endowment (CODE) today announced the second ever C.O.D.E. Bowl presented by USAA on December 11. The C.O.D.E. Bowl is the Endowment’s cornerstone charity event to raise awareness and funds for veteran employment. For the first time ever, all five U.S. Department of Defense military branches and UK military are participating with members from their own esports teams. This year’s C.O.D.E. Bowl includes three new teams making their debut from the US Marine Corps, US Air Force and the US Space Force. In addition, with the participation from the United Kingdom’s British Army, Royal Air Force, and Royal Navy, the C.O.D.E. Bowl will also be the first trans-Atlantic military esports competition to feature all of these branches.

“We are proud to have the United States and the United Kingdom militaries come together to participate in the C.O.D.E. Bowl,” said Dan Goldenberg, Executive Director of the Call of Duty Endowment. “This will be the first time all military branches have come together for a spirited esports competition with the added bonus of raising awareness for veteran employment and we couldn’t be more excited to partner with USAA to make this happen.”

The C.O.D.E. Bowl kicks off at 10:00 a.m. Pacific, December 11, and will feature eight teams each captained by a popular Call of Duty streamer teamed up with another top influencer and service members from the United States and the United Kingdom, all competing in the newly-released Call of Duty®: Black Ops Cold War in a tournament-style competition. The action will be broadcast live on the Call of Duty YouTube and Twitch channels. Each team will be also be coached by a Call of Duty League professional who will provide strategy, tips and recommendations prior to the event.

“C.O.D.E. Bowl is a premiere gaming event made even more impactful by the work of the Endowment to help place veterans into careers following their military service,” said USAA Chief Brand Officer Tony Wells, who was an infantry officer in the US Marines. “USAA is proud to support C.O.D.E. Bowl and expand our involvement in esports as a way to celebrate military members and veterans and help them connect with each other through games they love.”

Participating teams from the military include players from the United States Air Force, Army, Marine Corps, Navy and Space Force, and UK players from the British Army, Royal Navy and Royal Air Force. Streamers joining these teams include CouRage, LEGIQN, Huskerrs, Swagg, TeeP, Espresso, Vikkstar, Tommey, C9Emz, Spratt and more to be announced soon.

In addition to being the first all-service esports competition of its caliber, the C.O.D.E. Bowl, presented by USAA, is centered on impact. Ram Trucks will be giving away a 2021 Ram 1500 Built To Serve special edition truck to a deserving veteran recently placed into a job through the Endowment’s support. Scuf Controllers is also an event partner, for the second year in a row. All net proceeds from the event will be used to place veterans into high-quality jobs.

The Call of Duty Endowment has funded the placement of more than 77,000 vets into high quality employment since its inception and aims to place 100,000 veterans into meaningful jobs by 2024. The Endowment’s 2019 cost to place a veteran was $499, providing employment at 1/6 the cost of US Department of Labor efforts.

To help get veterans back to work, please visit: www.callofdutyendowment.org/help. In compliance with federal rules, all participating U.S. military esports teams will not be endorsing or participating in any fundraising activities associated with any organization, including the Call of Duty Endowment.

About the Call of Duty Endowment

The Call of Duty Endowment is a non-profit organization co-founded by Bobby Kotick, CEO of Activision Blizzard. The Endowment seeks to help veterans find high-quality careers by supporting groups that prepare them for the job market and by raising awareness of the value vets bring to the workplace. For more information about the Call of Duty Endowment, please visit www.callofdutyendowment.org.

About USAA

Founded in 1922 by a group of military officers, USAA is among the leading providers of insurance, banking and investment and retirement solutions to nearly 13 million members of the U.S. military, veterans who have honorably served and their families. Headquartered in San Antonio, Tex., USAA has offices in seven U.S. cities and three overseas locations and employs more than 35,000 people worldwide. Each year, the company contributes to national and local nonprofits in support of military families and communities where employees live and work. For more information about USAA, follow us on Facebook or Twitter (@USAA), or visit usaa.com.

ACTIVISION, CALL OF DUTY, and CALL OF DUTY BLACK OPS are trademarks of Activision Publishing, Inc. All other trademarks and trade names are the properties of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005278/en/

Kelvin Liu

Director, Corporate Communications

Activision Blizzard

310.255.2213

[email protected]

KEYWORDS: California Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Electronic Games Other Defense Entertainment Public Policy/Government Philanthropy White House/Federal Government Fund Raising Foundation Defense

MEDIA:

Logo

UroGen Pharma Announces Podium Presentation of Final Jelmyto^® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

• Clinically Meaningful Response Underscores Potential for Jelmyto to Become New Standard of Care for Patients with Low-Grade Upper Tract Urothelial Cancer
• Of the 58% of Patients who Achieved a Complete Response, 12-Month Durability of Response Estimated at 81.8% by Kaplan-Meier Analysis
• Median Time to Recurrence was Not Reached

PRINCETON, N.J.–(BUSINESS WIRE)–
UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the presentation of final data from the UGN-101 Jelmyto^® (mitomycin) for pyelocalyceal solution Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC). The results will be presented as a virtual podium presentation at the 21^st Annual Meeting of the Society of Urologic Oncology (SUO):

• Oral Session: Best of Bladder Cancer
• Abstract #: 1003
• Title: Durability of Response to Chemoablative Treatment of Low-Grade Upper Tract Urothelial Carcinoma with a Mitomycin-Containing Reverse Thermal Hydrogel: Final Results of the OLYMPUS Trial
• Presenter: Surena F. Matin, M.D., Professor of Urology at The University of Texas MD Anderson Cancer Center in Houston, TX
• Session Date & Time: Saturday, December 5, 2020; 2:00 pm Eastern Time

Final results from the Phase 3 OLYMPUS trial of Jelmyto, the first and only non-surgical kidney-sparing treatment approved by the U.S. Food and Drug Administration (FDA) for adults with LG-UTUC, show that Jelmyto demonstrated clinically meaningful response in adults with LG-UTUC. In both the OLYMPUS intent-to-treat population and in the sub-population of patients who were deemed to have unresectable disease at study entry, 58% of patients achieved a complete response (CR) with durability of response at 12-months estimated to be 81.8% by Kaplan-Meier analysis. Median time to recurrence was not reached.

“Current options for patients with low-grade upper tract urothelial carcinoma are not optimal. They include multiple endoscopic procedures or the removal of the kidney and ureter, both of which have consequences impacting patient health and quality of life,” said Surena F. Matin, M.D., Professor of Urology at The University of Texas MD Anderson Cancer Center in Houston, TX and Investigator of the OLYMPUS trial. “The results of the OLYMPUS study represent the first prospective trial in this space, supporting the use of Jelmyto as a less-invasive, kidney-preserving, durable treatment for low-grade upper tract urothelial carcinoma, which may reduce the need for multiple endoscopic procedures or loss of a kidney.”

The safety profile in the final OLYMPUS data was consistent with previously reported results. The most common adverse events (AE) were uretic stenosis, urinary tract infection, hematuria, flank pain, nausea, dysuria, renal dysfunction, abdominal pain and vomiting.

About the Phase 3 OLYMPUS Trial

OLYMPUS (Optimized DeLiverY of Mitomycin for Primary UTUC Study) is an open-label, single-arm Phase 3 clinical trial of UGN-101, Jelmyto (mitomycin) for pyelocalyceal solution, to evaluate the safety, tolerability and tumor ablative effect of Jelmyto in patients with low-grade UTUC. Seventy-one patients were treated at clinical sites across the United States and Israel. Study participants were treated with six weekly instillations of Jelmyto administered via a standard catheter. Four to six weeks following the last instillation, patients underwent a Primary Disease Evaluation (PDE) to determine Complete Response (CR), the primary endpoint of the study. PDE involved a ureteroscopy and wash cytology, a standard microscopic test of cells obtained from the urine to detect cancer and for cause biopsy. Patients who achieved a CR at the PDE timepoint were continued onto the maintenance phase of the trial, during which they were to receive monthly maintenance instillations for up to 12 months to determine the durability of response with Jelmyto.

About Jelmyto^®

Jelmyto (mitomycin) for pyelocalyceal solution, is a drug formulation of mitomycin indicated for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Utilizing the RTGel™ technology platform, UroGen’s proprietary sustained release, hydrogel-based formulation, Jelmyto is designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. Jelmyto is delivered to patients using standard ureteral catheters or nephrostomy tube. The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC. On April 15, 2020, the FDA approved Jelmyto, making it the first drug approved for the treatment of LG-UTUC in adult patients.

APPROVED USE FOR JELMYTO

JELMYTO^® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

IMPORTANT SAFETY INFORMATION

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

• are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  
  Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.
  
  Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.
• are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
• Tell your healthcare provider if you takewater pills (diuretic).

How will I receive JELMYTO?

• Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
• You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider’s instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
• JELMYTO is given to your kidney through a tube called a catheter.
• During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.

After receiving JELMYTO:

• JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.
• To urinate, males and females shouldsit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.
• Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

JELMYTO may cause serious side effects, including:

• Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.
• Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.

The most common side effects of JELMYTO include: side pain, urinary tract infection, blood in your urine, kidney problems, tiredness, nausea, stomach pain, trouble with urination, vomiting, low red blood cell count, frequent urination, itching, chills, and fever.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda/gov/medwatch or call 1‑800‑FDA‑1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see JELMYTO Full Prescribing Information, including the Patient Information at www.jelmyto.com.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of Jelmyto^®, to transform the treatment of LG-UTUC; the potential for Jelmyto to become the new standard of care for patients with LG-UTUC;the potential for the use of Jelmyto to reduce the need for multiple endoscopic procedures or loss of a kidney; and the potential of UroGen’s proprietary RTGel™ technology platform to improve therapeutic profiles of existing drugs. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities, including complications resulting from the ongoing COVID-19 pandemic; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and personnel; and any negative effects on UroGen’s business, commercialization and product development plans caused by or associated with COVID-19. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form 10-Q filed with the SEC on November 9, 2020, and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005265/en/

INVESTOR CONTACT:

Sara Blum Sherman

Head of Investor Relations

[email protected]

609-467-4975

MEDIA CONTACT:

Eric Van Zanten

Head of Communications

[email protected]

610-529-6219

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA: